April 23, 2020

Andrew Jackson
Chief Financial Officer
Ra Medical Systems, Inc.
2070 Las Palmas Drive
Carlsbad, California 92011

       Re: Ra Medical Systems, Inc.
           Registration Statement on Form S-1
           Filed April 16, 2020
           File No. 333-237701

Dear Mr. Jackson:

       We have limited our review of your registration statement to those
issues we have
addressed in our comment. In our comment, we may ask you to provide us with
information so
we may better understand your disclosure.

        Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comment applies to your facts
and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

        After reviewing any amendment to your registration statement and the
information you
provide in response to this comment, we may have additional comments.

Registration Statement on Form S-1

Risk Factors
Our certificate of incorporation provides that the Court of Chancery of the
State of Delaware and
the federal district courts..., page 60

1.     We note that your forum selection provision discussed in this risk
factor and on page 70
       identifies the Court of Chancery of the State of Delaware as the
exclusive forum for
       certain litigation, including any "derivative action." Please disclose
whether this provision
       applies to actions arising under the Exchange Act. We note in this
regard that Section 27
       of the Exchange Act creates exclusive federal jurisdiction over all
suits brought to enforce
       any duty or liability created by the Exchange Act or the rules or
regulations thereunder. If
       this provision does not apply to actions arising under the Exchange Act,
please tell us how
       you will inform investors in future filings that the provision does not
apply to any actions
 Andrew Jackson
Ra Medical Systems, Inc.
April 23, 2020
Page 2
         arising under the Exchange Act. We also note that your forum selection
provision
         identifies the federal district courts of the United States as the
exclusive forum for
         resolving any complaint asserting a cause of action arising under the
Securities Act. With
         respect to this exclusive federal forum provision, please also revise
your prospectus to
         state that there is uncertainty as to whether a court would enforce
such provision and that
         investors cannot waive compliance with the federal securities laws and
the rules and
         regulations thereunder.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Courtney Lindsay at (202) 551-7237 or Ada Sarmento at
(202) 551-3798
with any other questions.



FirstName LastNameAndrew Jackson                               Sincerely,
Comapany NameRa Medical Systems, Inc.
                                                               Division of
Corporation Finance
April 23, 2020 Page 2                                          Office of Life
Sciences
FirstName LastName